Subscribe to AI For Pharma Growth’s news feed.
Click on “Follow” and decide if you want to get news from AI For Pharma Growth via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to AI For Pharma Growth comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from AI For Pharma Growth which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: AI For Pharma Growth
Is this your feed? Claim it!
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Jacek Marczyk, co-founder and CEO of BioDynLab, about a contrarian view of computational drug discovery: that the next leap may come not from more data and bigger models, but from physics.
Dr. Marczyk brings a background in aerospace engineering, automotive, Silicon Graphics and complexity science....
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores the AI capability problem pharma has not properly named: training that works in the room, but fails to hold inside the organisation.
Dr Andree explains why one-off workshops, generic AI fluency programmes and broad learning platforms are not enough. They may teach people what AI is, what it can do an...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Tom Coates, CEO of Presentient, about why interim analysis in clinical trials is ready for a major upgrade.
Interim analyses allow sponsors to look at trial data mid-flight and assess whether a study is likely to succeed or fail, using pre-specified rules. But Tom explains that many phase two and three...
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores why many pharma teams do not have an AI problem at all. They have a capability problem.
Dr Andree starts with a simple question: when was your team last properly trained on AI for their specific role? Not when they were given access to tools, licences or a generic use policy, but when they were train...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Nijat Ahmadov, CEO of Nucs AI, about molecular imaging as one of pharma’s most underused data assets.
Nijat explains why PET, CT and other molecular imaging data remain largely “untouched”: clinically valuable and created at scale, but still too often trapped in qualitative reads rather than structured...